DGX · Quest Diagnostics Inc
Price
Snapshot
50 fields · last close| Market Cap | $25.94B |
| P/E | 24.42 |
| Float | 109.8M |
| Beta | 0.56 |
| Volatility | 14.0% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 82.4 |
| Price | 234.65 |
| Change | −0.15% |
| Prev Close | 235.00 |
| Open | 239.67 |
| Day Low | 233.56 |
| Day High | 240.75 |
| Avg Vol | 1 |
| Avg $ Vol | $242.6M |
| 52W High | 248.84 |
| 52W Low | 171.18 |
| 52W Pos | 81.7% |
| From High | −5.70% |
| From Low | +37.08% |
| Max DD 1Y | −11.94% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.43% |
| SMA 50 | −1.17% |
| SMA 200 | +12.35% |
| RSI (14) | 50.7 |
| Vol 30D | 24.8% |
| Vol 90D | 25.0% |
| 1Y Range | 171–249 |
| Daily bars | 536 |
| Perf Week | +1.74% |
| Perf Month | −5.03% |
| Perf Quarter | +13.17% |
| Perf Half Y | +20.50% |
| Perf Year | +25.43% |
| Perf YTD | +35.02% |
| Prev Day | −0.15% |
| Clavix | A- |
| Debt / Eq | 0.79 |
| Curr Ratio | 1.04 |
| Int Cover | 7.1× |
| FCF Margin | 12.3% |
| Rev Growth | +11.8% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 7 / 49 |
What DGX does
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer’s disease; and women’s health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services.
Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions.
Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Clavix risk grade
regraded every trading dayDGX grades A-, 82.4 of 100. Steadiest on News Sentiment (68), most exposed on Sector Resilience (64, mixed). 2 of the 4 weighted dimensions sit above the Health Care median. Ranks 7 of 49 in Health Care by Clavix score.
How rough the ride is
| DGX | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.56 | 0.84 |
| Volatilityannualized | 14.0% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −11.9% | — |
| Typical daily movemedian absolute daily change | 0.79% | — |
| Days beyond ±3%of the last 252 sessions | 12 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| DGX | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.56 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| DGX | |
|---|---|
| 1 week | +1.7% |
| 1 month | −5.0% |
| Year to date | +35.0% |
| 1 year | +25.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| DGX | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 6 Aug |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 15 · 4 |
| Directionarticles whose tone is improving vs worsening | 15 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| DGX | |
|---|---|
| Revenue growthyear over year | +11.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openQuest Diagnostics is heading into its third-quarter earnings report with analysts expecting both revenue and earnings per share to grow, driven by strong demand for clinical testing, advanced diagnostic services, and operational efficiencies. The article does not report actual Q3 results, only sets the stage ahead of the release.
Quest Diagnostics (DGX) announced that Executive Vice President Catherine T. Doherty will retire in July 2027 and step into a new strategic advisory role starting November 1, 2026.
Quest Diagnostics (DGX) announced that executive Catherine T. Doherty will retire in July 2027, transitioning first to an Executive Vice President role starting November 1, 2026, overseeing health systems, the Corewell Health joint venture, and Project Nova (a multi-year overhaul of order-to-cash processes and IT). Her base salary stays at $650,000, her annual cash incentive target stays at 80% of salary, and she receives a new equity grant of $1.2 million in restricted stock units.
A study published in The Journal of Molecular Diagnostics showed that Quest Diagnostics' Haystack MRD blood test accurately detected remaining and returning cancer in patient samples from the major DYNAMIC colorectal cancer trial series, and the test's performance was also validated across 23 solid tumor types.
A nonprofit (Who We Play For), Myelai, and Unless Health have launched a cardiac screening program at Quest Diagnostics' Sheldon Road location in Tampa, offering ECG screenings to families. The program ties into Florida's Second Chance Act, which made the state the first to require ECGs for high school athletes.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| LH | Labcorp Holdings Inc | A- | $25.79B | 25.73 | 0.89 | Compare |
| ALC | Alcon AG | B+ | $27.54B | 40.81 | 1.07 | Compare |
| STE | STERIS plc | A- | $21.71B | 26.97 | 0.88 | Compare |
| THC | Tenet Healthcare Corp | B | $21.52B | 9.60 | 1.22 | Compare |
| GEHC | GE Healthcare Technologies Inc | B | $31.42B | 15.83 | 0.83 | Compare |
| GH | Guardant Health Inc | C+ | $21.28B | — | 1.71 | Compare |
| DXCM | Dexcom Inc | B | $32.47B | 32.48 | 1.44 | Compare |
| RMD | Resmed Inc | B+ | $33.61B | 22.06 | 0.77 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.